Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.

Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I, Pullarkat V, Wei H, Kreuzbauer G.

Eur J Haematol. 2014 Jul 14. doi: 10.1111/ejh.12415. [Epub ahead of print]

PMID:
25039799
[PubMed - as supplied by publisher]
2.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
[PubMed - indexed for MEDLINE]
3.

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL.

Lancet. 2008 Feb 2;371(9610):395-403. doi: 10.1016/S0140-6736(08)60203-2.

PMID:
18242413
[PubMed - indexed for MEDLINE]
4.

Romiplostim: a review of its use in immune thrombocytopenia.

Keating GM.

Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. Review.

PMID:
22316355
[PubMed - indexed for MEDLINE]
5.

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.

Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25.

PMID:
21706145
[PubMed - indexed for MEDLINE]
6.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.

Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.

Blood. 2011 Oct 20;118(16):4338-45. doi: 10.1182/blood-2011-03-340166. Epub 2011 Aug 10.

PMID:
21832276
[PubMed - indexed for MEDLINE]
Free Article
7.

The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.

Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2014 Aug;39(4):376-82. doi: 10.1111/jcpt.12156. Epub 2014 Apr 4.

PMID:
24702274
[PubMed - in process]
8.

Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.

Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N.

Appl Health Econ Health Policy. 2013 Oct;11(5):457-69. doi: 10.1007/s40258-013-0044-y. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):687.

PMID:
23857462
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.

Al-Jafar H, Giagounidis A, El-Rashaid K, Al-Ali M, Hakim AA.

Ann Pharmacother. 2012 Nov;46(11):e31. doi: 10.1345/aph.1R134. Epub 2012 Oct 31.

PMID:
23115229
[PubMed - indexed for MEDLINE]
10.

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.

Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.

PMID:
23432528
[PubMed - indexed for MEDLINE]
11.

A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia.

Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, Gleeson M, Danese M, Deuson R.

Curr Med Res Opin. 2012 May;28(5):789-96. doi: 10.1185/03007995.2012.684046. Epub 2012 Apr 25.

PMID:
22494019
[PubMed - indexed for MEDLINE]
12.

An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.

Int J Hematol. 2012 Jun;95(6):652-9. doi: 10.1007/s12185-012-1065-2. Epub 2012 Apr 25.

PMID:
22532046
[PubMed - indexed for MEDLINE]
13.

Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).

Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ.

Value Health. 2011 Jan;14(1):90-6. doi: 10.1016/j.jval.2010.10.017.

PMID:
21211490
[PubMed - indexed for MEDLINE]
14.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.

Blood. 2011 Jul 7;118(1):28-36. doi: 10.1182/blood-2010-10-313908. Epub 2011 Apr 18.

PMID:
21502541
[PubMed - indexed for MEDLINE]
Free Article
15.

Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.

Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V.

J Med Econ. 2013;16(2):318-26. doi: 10.3111/13696998.2012.756400. Epub 2012 Dec 17.

PMID:
23216012
[PubMed - indexed for MEDLINE]
16.

Romiplostim for the treatment of primary immune thrombocytopenia.

Janssens A.

Expert Rev Hematol. 2012 Apr;5(2):133-44. doi: 10.1586/ehm.12.6.

PMID:
22475281
[PubMed - indexed for MEDLINE]
17.

Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.

Stasi R, Murali M, Michel M, Viallard JF, Giagounidis A, Janssens A, Legg J, Deuson R, Danese MD.

Int J Hematol. 2012 Jul;96(1):26-33. doi: 10.1007/s12185-012-1088-8. Epub 2012 May 5.

PMID:
22562409
[PubMed - indexed for MEDLINE]
18.

Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.

Newland A.

Eur J Haematol Suppl. 2009 Mar;(71):20-5. doi: 10.1111/j.1600-0609.2008.01209.x. Review.

PMID:
19200304
[PubMed - indexed for MEDLINE]
19.

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.

Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P.

Eur J Haematol. 2013 Nov;91(5):423-36. doi: 10.1111/ejh.12181. Epub 2013 Sep 17.

PMID:
23927437
[PubMed - in process]
20.

Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.

Chouhan JD, Herrington JD.

Pharmacotherapy. 2010 Jul;30(7):666-83. doi: 10.1592/phco.30.7.666. Review.

PMID:
20575632
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk